WHO's Good Manufacturing Practice framework is built on a small set of core documents, and confusing them is a common mistake in generic content covering this topic.
| Document | Year | What it covers |
|---|---|---|
| TRS 986 | 2014 | Core GMP principles and the model Pharmaceutical Quality System — still the foundational document. |
| TRS 1044 | 2022 | Updated annexes, including sterile products (Annex 2) and R&D facilities (Annex 6). |
| TRS 1052 | 2023 | WHO GMP requirements specific to excipients. |
The core principle most content skips
WHO's Pharmaceutical Quality System (PQS) concept explicitly requires senior management ownership and participation "at all levels" — including suppliers and distributors, not just the internal QA department. A quality system that only reaches as far as the factory gate doesn't fully satisfy WHO's PQS scope.
Is WHO-GMP mandatory in India?
No — revised Schedule M is India's mandatory domestic GMP standard. WHO-GMP certification is a separate, typically voluntary process pursued by manufacturers targeting export markets or WHO Prequalification — a program many UN agencies and international procurement bodies require before purchasing from a manufacturer, particularly for priority medicines addressing HIV, malaria, TB, and similar conditions.
How WHO-GMP relates to Schedule M
Revised Schedule M (notified December 2023) was explicitly designed to align Indian domestic GMP with WHO TRS 986 — closing the historical gap between India's domestic standard and the international benchmark its export-oriented manufacturers were already being measured against. In practice, a facility that's genuinely Schedule M-compliant under the revised standard has already built most of the foundation WHO-GMP certification requires — though WHO-GMP still involves its own separate certification and assessment process.
Ready to see this in your own lab? Book a free ValiCore demo.